Articles

The incidence of hematologic adverse events observed in patients with advanced ovarian cancer treated with niraparib at an individualized starting dose of 200 mg once daily was lower than that reported with a dose of 300 mg once daily. Read More ›

An analysis of real-world data suggests that patients with a platinum-free interval of ≥12 months experienced a trend toward a greater benefit from subsequent platinum-based chemotherapy after PARP inhibition. For patients with a platinum-free interval of 6 to 12 months, the benefit was similar to that seen in patients receiving nonplatinum chemotherapy. Read More ›

An on-demand online video panel discussion regarding the use of PARP inhibitors in patients with newly diagnosed advanced ovarian cancer resulted in a positive educational impact among oncologists and obstetrician-gynecologists. Read More ›

Population-based personalized ovarian cancer risk stratification is feasible and acceptable. Participants reported high satisfaction without a negative impact on psychological health or quality of life. Read More ›

The level of CA 19-9, expression of HE4, and the presence of massive ascites or positive lymph nodes are important prognostic factors for overall survival in patients with ovarian clear-cell carcinoma. Read More ›

In the MIRRORS study, researchers aim to determine the feasibility of a randomized controlled trial of robotic interval debulking surgery for patients with ovarian cancer. While robotic surgery is unlikely to be suitable for all cases of ovarian cancer, researchers hope that robotic surgery may provide improved quality of life and recovery in selected women. Read More ›

The efficacy and safety of treatment with niraparib was similar in older patients and in those aged 65 years. An individualized starting dose decreased the rate of thrombocytopenia adverse events in older patients. Read More ›

Contemporaneous monitoring of HER2 status with circulating tumor cells may help to identify patients who may benefit from modifying the treatment approach with anti-HER2 therapy, through supplementation or switching to another therapy as necessary based on receptor switch. Read More ›

The potential role of the combination of pertuzumab, hormone therapy, plus an aromatase inhibitor as first-line treatment for HER2-positive metastatic or locally advanced breast cancer is further supported by the final analysis of the PERTAIN trial. Read More ›

Among patients with HER2-positive metastatic breast cancer, the healthcare resource utilization of brain metastases is significantly higher when compared with patients without brain metastases, underscoring the critical need for effective systemic therapies that improve outcomes and decrease the burden of disease. Read More ›